

Yves Allory

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5041391/publications.pdf>

Version: 2024-02-01

32
papers

1,681
citations

567281

15
h-index

454955

30
g-index

35
all docs

35
docs citations

35
times ranked

2235
citing authors

#	ARTICLE	IF	CITATIONS
1	A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2020, 77, 420-433.	1.9	741
2	EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. <i>Science Translational Medicine</i> , 2014, 6, 244ra91.	12.4	304
3	Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses. <i>European Urology</i> , 2021, 79, 214-221.	1.9	130
4	Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2013-2022.	1.6	75
5	Renal Medullary Carcinoma: Establishing Standards in Practice. <i>Journal of Oncology Practice</i> , 2017, 13, 414-421.	2.5	52
6	Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment. <i>Annals of Oncology</i> , 2016, 27, 1311-1316.	1.2	49
7	Ductal adenocarcinoma of the prostate: Clinical and biological profiles. <i>Prostate</i> , 2017, 77, 1242-1250.	2.3	26
8	Contemporary assessment of the correlation between Bosniak classification and histological characteristics of surgically removed atypical renal cysts (UroCCR-12 study). <i>World Journal of Urology</i> , 2018, 36, 1643-1649.	2.2	25
9	Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility. <i>Modern Pathology</i> , 2018, 31, 1270-1281.	5.5	24
10	Kidney Cancer Pathology in the New Context of Targeted Therapy. <i>Pathobiology</i> , 2011, 78, 90-98.	3.8	23
11	Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear cell renal cell carcinoma patients treated with sunitinib. <i>BJU International</i> , 2016, 118, 890-901.	2.5	23
12	Pure Large Nested Variant of Urothelial Carcinoma (LNUC) Is the Prototype of an FGFR3 Mutated Aggressive Urothelial Carcinoma with Luminal-Papillary Phenotype. <i>Cancers</i> , 2020, 12, 763.	3.7	22
13	Risk factors associated with positive surgical margins™ location at radical cystectomy and their impact on bladder cancer survival. <i>World Journal of Urology</i> , 2021, 39, 4363-4371.	2.2	22
14	High Positive Correlations between ANRIL and p16-CDKN2A/p15-CDKN2B/p14-ARF Gene Cluster Overexpression in Multi-Tumor Types Suggest Deregulated Activation of an ANRIL-ARF Bidirectional Promoter. <i>Non-coding RNA</i> , 2019, 5, 44.	2.6	21
15	Implication of NPM1 phosphorylation and preclinical evaluation of the nucleoprotein antagonist N6L in prostate cancer. <i>Oncotarget</i> , 2016, 7, 69397-69411.	1.8	17
16	Stromal lymphocyte infiltration is associated with tumour invasion depth but is not prognostic in high-grade T1 bladder cancer. <i>European Journal of Cancer</i> , 2019, 108, 111-119.	2.8	16
17	Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial. <i>Contemporary Clinical Trials Communications</i> , 2020, 17, 100536.	1.1	13
18	Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e45-e52.	1.9	12

#	ARTICLE	IF	CITATIONS
19	Reference-free transcriptome exploration reveals novel RNAs for prostate cancer diagnosis. <i>Life Science Alliance</i> , 2019, 2, e201900449.	2.8	12
20	Multilayer spectrum of intratumoral heterogeneity in basal bladder cancer. <i>Journal of Pathology</i> , 2022, 256, 108-118.	4.5	12
21	BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	11
22	Identification of a Novel Biomarker Signature Associated with Risk for Bone Metastasis in Patients with Renal Cell Carcinoma. <i>International Journal of Biological Markers</i> , 2010, 25, 112-115.	1.8	10
23	Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort. <i>Journal of Clinical Pathology</i> , 2023, 76, 126-132.	2.0	7
24	Overexpression of Nucleolin and Associated Genes in Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4491.	4.1	7
25	Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 554-562.	1.9	6
26	Refining the use of neoadjuvant chemotherapy in locally advanced bladder cancer: from conviction to optimization. <i>Translational Andrology and Urology</i> , 2018, 7, 757-759.	1.4	4
27	Parafibromin as a new immunohistochemistry staining to improve pathologic diagnosis of renal oncocytoma: Analysis of 225 renal tumors.. <i>Journal of Clinical Oncology</i> , 2011, 29, 408-408.	1.6	1
28	The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory Analysis. <i>International Journal of Surgical Pathology</i> , 2023, 31, 157-166.	0.8	1
29	Reply to S. Zeng et al. <i>Journal of Clinical Oncology</i> , 0, , .	1.6	1
30	Left lobe of the prostate during clinical prostate cancer screening: the dark side of the gland for right-handed examiners. <i>Prostate Cancer and Prostatic Diseases</i> , 2014, 17, 157-162.	3.9	0
31	Clasificaci3n de los tumores testiculares. <i>EMC - UrologÃa</i> , 2021, 53, 1-15.	0.0	0
32	Long-term results and prognostic factors for survival following adjuvant chemotherapy (AC) for muscle-invasive urothelial bladder cancer (UC): A French retrospective multicenter cohort.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4549-4549.	1.6	0